Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: July 22, 2004
Last updated: January 19, 2012
Last verified: January 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2006
  Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)